2021 ASCO in the vision of liver surgeons

doi:10.3969/j.issn.1009-976X.2021.03.003

Abstract

Abstract: The 57th Annual Meeting of the American Society of Clinical Oncology（ASCO） was held online as scheduled. The meeting reported on a number of clinical research results and progress related to hepatocellular carcinoma. In this report, we summarize some selected presentations involving surgical-related treatments that may be of interest to liver surgeons, such as neoadjuvant, auxiliary, perioperative, and conversion therapy.

Key words: hepatocellular carcinoma, neoadjuvant, auxiliary, perioperative, conversion therapy

摘要： 第57届美国临床肿瘤学会年会如期在线上召开。会议报道了肝癌最新临床研究结果和进展。本文就本次年会上与外科相关的肝癌治疗,如新辅助、辅助、围手术期、转化治疗等最新进展进行综合述评。

关键词: 肝细胞癌, 外科治疗, 新辅助/辅助治疗, 围手术期, 转化治疗

CLC Number:

R735.7

DING Chen-chen, SONG Xing-dong, ZHANG Lei. 2021 ASCO in the vision of liver surgeons[J]. Lingnan Modern Clinics In Surgery, 2021, 21(03): 265-271.

丁陈陈, 宋兴东, 张磊. 肝脏外科医生眼中的2021 ASCO[J]. 岭南现代临床外科, 2021, 21(03): 265-271.

References

[1] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中国实用外科杂志, 2020,40(2): 121-138.
[2] Li SH, Zhong C, Li Q, et al. Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial[J]. J Clin Oncol,2021, 39, (suppl 15): 4008.
[3] Mazzaferro V, Llovet JM, Miceli R, et al.Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis[J]. Lancet Oncol, 2009, 10(1):5-7.
[4] 夏勇,杨田,王葵. 肝细胞癌肝切除术后复发预防和治疗中国专家共识(2020版)[J].中国实用外科杂志,2021,41(1):20-30.
[5] SHI M, LI QJ, HE MK, et al.Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil, and leucovorin (FOLFOX) versus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC): A randomised phase Ⅲ trial[J]. Ann Oncol, 2020, 31: S688.
[6] Shen JY, Li C, Wen TF, et al.Transplantation versus hepatectomy for HCC beyond the Milan criteria: A propensity score analysis[J]. Int J Surg, 2017, 44:33-42.
[7] Lu SD, Li L, Liang XM, et al.Updates and advancements in the management of hepatocellular carcinoma patients after hepatectomy[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(11):1077-1088.
[8] Akateh C, Black SM, Conteh L, et al.Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma[J]. World J Gastroenterol, 2019, 25:3704-3721.
[9] Kudo M, Ueshima K, Nakahira S, et al.Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis[J]. J Clin Oncol,2021, 39(suppl 15): 4070.
[10] Bruix J, Takayama T, Mazzaferro V, et al.Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo- controlled trial[J]. Lancet Oncol, 2015, 16(13):1344-1354.
[11] Wang Z,Ren Z,Chen Y,et al.Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection:A Randomized Controlled Study[J]. Clin Cancer Res, 2018, 24(9):2074-2081.
[12] Wei W, Jian PE, Li SH, et al.Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion:a randomized clinical trial of efficacy and safety[J]. Cancer Commun, 2018, 38(1):1-12.
[13] 中国临床肿瘤学会指南工作委员会.原发性肝癌诊疗指南(2020年版)[M].人民卫生出版社:北京,2020.
[14] Kudo M, Ueshima K, Ike Da M, et al.Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial[J]. Gut, 2019, 69(8):1492-1501.
[15] Wu Z, Wang Z, Zhang L, et al.Preliminary results of the phase II ALTER-H004: Anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of post surgery recurrence[J]. J Clin Oncol, 2021, 39(suppl 15):e16125.
[16] Kaseb AO, Cao HST, Mohamed YI, et al.Final results of a randomized, open label, perioperative phase IIstudy evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC[J]. J Clin Oncol, 2021, 38(suppl 15):4599.
[17] Xia YX, Wang P, Pu LY, et al.Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC): A prospective phase Ⅱ study[J]. J Clin Oncol, 2021, 39(suppl 15): 4082.
[18] Zhang T, Merle P, Wang H, et al.Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?[J]. Hepatobiliary Surg Nutr, 2021, 10(2):180-192.
[19] Lau WY, Lai EC, Lai EC.Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability[J]. Ann Surg Oncol,2007,14(12):3301-3309.
[20] Zhang W, Hu B, Han J, et al.A real-world study of PD-1 inhibitors combined with TKIs for HCC with major vascular invasion as the conversion therapy: A prospective, non-randomized, open-label cohort study[J]. Ann Oncol, 31(suppl 6): S1307.
[21] Zhang WW, Lu SH, Hu BY, et al.PD-1 inhibitor combined with lenvatinib for unresectable liver cancer as the conversion therapy: An open-label, non-randomized, phase IV study[J]. J Clin Oncol, 2021, 39(suppl 15):e16173.